MasterCard Cl A (MA) Falls 3.53% for January 04

Equities Staff |

One of the S&P 500’s big losers for Monday January 04 was MasterCard Cl A (MA). The company’s stock fell 3.53% to $93.92 on volume of 3.68 million shares.

The stock opened the day at 95.37 and traded between a low of $93.72 and a high of $95.59. The stock finished the day down $3.44 per share. MasterCard Cl A has an average daily volume of 3.99 million and a total float of 1.11 billion shares. The 50-day SMA for MasterCard Cl A is $98.62 and its 200-day SMA is $94.10. The high for the stock over the last 52 weeks is $101.76 and the low is $74.61.

MasterCard Inc is a technology company in the payments industry that connects consumers, financial institutions, merchants, governments and businesses, enabling them to use electronic forms of payment instead of cash and checks.

MasterCard Cl A is centered in Purchase, NY, and has 10,300 employees. Today’s trading day leaves the company with a market cap of $104.15 billionwith a P/E Ratio of 29.9. The company has a P/S ratio of 15.1, P/B ratio of 16.83, and a 62.6.

For a complete fundamental analysis analysis of MasterCard Cl A, check out’s Stock Valuation Analysis report for MA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…